AR018639A1 - Fenoxipropanolaminas, procedimiento para su preparacion y composicion farmaceutica que las contienen, su utilizacion para la manufactura de un medicamentoy compuestos para su exclusivo uso en dicho procedimiento - Google Patents
Fenoxipropanolaminas, procedimiento para su preparacion y composicion farmaceutica que las contienen, su utilizacion para la manufactura de un medicamentoy compuestos para su exclusivo uso en dicho procedimientoInfo
- Publication number
- AR018639A1 AR018639A1 ARP990102731A ARP990102731A AR018639A1 AR 018639 A1 AR018639 A1 AR 018639A1 AR P990102731 A ARP990102731 A AR P990102731A AR P990102731 A ARP990102731 A AR P990102731A AR 018639 A1 AR018639 A1 AR 018639A1
- Authority
- AR
- Argentina
- Prior art keywords
- alk
- group
- procedure
- compounds
- manufacture
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
Abstract
Fenoxipropanolaminas de formula (Ia) en la cual R1a representa hidrogeno, un grupo -S(O)z-(C1-4)-Alk, un grupo -CO(C1-C4)Alk, un grupo -NHSO2-(C1-4)Alk,un grupo NHCO(C1-4)Alk, un grupo 2-furilo o un halogeno; R2 represena hidrogeno o un grupo (C1-4)-Alk, un grupo -(C1-4)alcoxilo, un grupo halogeno, -COOH,-COO(C1-4) Alk, -CN, -CONR3R4, -NO2 -SO2NH2-NHSO2(C1-4)Alk; m y n son independientemente 0, 1 o 2; R3 y R4 representan independientemente hidrogeno o un grupo(C1-4)Alk, Z es 1 o 2; (C1-4)Alk designa un radical monovalente de un hidrocarbono C1-4 saturado de cadena recta o ramificada, y sus sales o solvatos,composicion farmacéutica que las contienen, procedimiento para su preparacion, su utilizacion para la manufactura de un medicamento y compuestos para suexclusivo uso en dicho procedimiento. Se ha hallado que las fenoxipropanolaminas que tienen un radical 1-(pirrol-2-il)piperidin-4-ilo sobre la amina poseen unaactividad agonista frente a los receptores beta 3 adrenérgicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9807660A FR2780057B1 (fr) | 1998-06-18 | 1998-06-18 | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
AR018639A1 true AR018639A1 (es) | 2001-11-28 |
Family
ID=9527517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990102731A AR018639A1 (es) | 1998-06-18 | 1999-06-09 | Fenoxipropanolaminas, procedimiento para su preparacion y composicion farmaceutica que las contienen, su utilizacion para la manufactura de un medicamentoy compuestos para su exclusivo uso en dicho procedimiento |
Country Status (12)
Country | Link |
---|---|
US (1) | US6649627B1 (es) |
EP (1) | EP1087961B1 (es) |
JP (1) | JP4563581B2 (es) |
AR (1) | AR018639A1 (es) |
AT (1) | ATE222250T1 (es) |
AU (1) | AU4048299A (es) |
CO (1) | CO5011052A1 (es) |
DE (1) | DE69902535T2 (es) |
ES (1) | ES2183557T3 (es) |
FR (1) | FR2780057B1 (es) |
GT (1) | GT199900102A (es) |
WO (1) | WO1999065895A1 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
AU2525801A (en) | 1999-12-17 | 2001-06-25 | Sanofi-Synthelabo | Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them |
FR2802533B1 (fr) * | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | Phenoxypropanolamines, leur preparation et leur application en therapeutique |
CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
SK632003A3 (en) * | 2000-07-13 | 2003-06-03 | Lilly Co Eli | Beta3 adrenergic agonists |
US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6509358B2 (en) | 2000-07-17 | 2003-01-21 | Wyeth | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6514991B2 (en) | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
US6444685B1 (en) * | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6458817B1 (en) | 2000-07-17 | 2002-10-01 | Wyeth | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
FR2817257B1 (fr) | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
SE0101038D0 (sv) * | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
FR2840301B1 (fr) * | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
KR101406415B1 (ko) | 2005-07-15 | 2014-06-19 | 미셀 테크놀로지즈, 인코포레이티드 | 제어된 형태의 약물 분말을 함유하는 중합체 코팅 |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
ATE549337T1 (de) | 2006-04-21 | 2012-03-15 | Novartis Ag | Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten |
PL2019657T3 (pl) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Powłoki zawierające wiele leków |
US8636767B2 (en) | 2006-10-02 | 2014-01-28 | Micell Technologies, Inc. | Surgical sutures having increased strength |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
JP5603598B2 (ja) | 2007-01-08 | 2014-10-08 | ミセル テクノロジーズ、インコーポレイテッド | 生物分解層を有するステント |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
WO2008148013A1 (en) | 2007-05-25 | 2008-12-04 | Micell Technologies, Inc. | Polymer films for medical device coating |
AU2009251504B2 (en) | 2008-04-17 | 2013-09-05 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
CA2730995C (en) | 2008-07-17 | 2016-11-22 | Micell Technologies, Inc. | Drug delivery medical device |
WO2011009096A1 (en) | 2009-07-16 | 2011-01-20 | Micell Technologies, Inc. | Drug delivery medical device |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
JP2012522589A (ja) | 2009-04-01 | 2012-09-27 | ミシェル テクノロジーズ,インコーポレイテッド | 被覆ステント |
CA2759015C (en) | 2009-04-17 | 2017-06-20 | James B. Mcclain | Stents having controlled elution |
WO2011097103A1 (en) | 2010-02-02 | 2011-08-11 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
WO2013012689A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
JP6330024B2 (ja) | 2013-03-12 | 2018-05-23 | マイセル・テクノロジーズ,インコーポレイテッド | 生体吸収性バイオメディカルインプラント |
WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
HUE049979T2 (hu) | 2017-03-20 | 2020-11-30 | Forma Therapeutics Inc | Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként |
BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI76551C (fi) * | 1980-11-06 | 1988-11-10 | Sandoz Ag | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat. |
GB2163150B (en) * | 1984-07-19 | 1988-05-25 | Sandoz Ltd | 3-aminopropoxyaryl derivatives |
US5145967A (en) * | 1989-04-20 | 1992-09-08 | Anaquest, Inc. | Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof |
US5340160A (en) | 1989-11-21 | 1994-08-23 | Wavin B.V. | Thermoplastic saddle in two parts for repairing or renovating a pipe line with branch pipe and repaired or renovated pipe with a saddle |
MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
-
1998
- 1998-06-18 FR FR9807660A patent/FR2780057B1/fr not_active Expired - Fee Related
-
1999
- 1999-06-04 CO CO99035290A patent/CO5011052A1/es unknown
- 1999-06-09 AR ARP990102731A patent/AR018639A1/es unknown
- 1999-06-10 US US09/719,640 patent/US6649627B1/en not_active Expired - Fee Related
- 1999-06-10 ES ES99923710T patent/ES2183557T3/es not_active Expired - Lifetime
- 1999-06-10 WO PCT/FR1999/001370 patent/WO1999065895A1/fr active IP Right Grant
- 1999-06-10 DE DE69902535T patent/DE69902535T2/de not_active Expired - Lifetime
- 1999-06-10 AU AU40482/99A patent/AU4048299A/en not_active Abandoned
- 1999-06-10 JP JP2000554720A patent/JP4563581B2/ja not_active Expired - Fee Related
- 1999-06-10 EP EP99923710A patent/EP1087961B1/fr not_active Expired - Lifetime
- 1999-06-10 AT AT99923710T patent/ATE222250T1/de not_active IP Right Cessation
- 1999-07-01 GT GT199900102A patent/GT199900102A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU4048299A (en) | 2000-01-05 |
WO1999065895A1 (fr) | 1999-12-23 |
EP1087961A1 (fr) | 2001-04-04 |
JP4563581B2 (ja) | 2010-10-13 |
DE69902535T2 (de) | 2003-04-10 |
EP1087961B1 (fr) | 2002-08-14 |
CO5011052A1 (es) | 2001-02-28 |
ES2183557T3 (es) | 2003-03-16 |
FR2780057A1 (fr) | 1999-12-24 |
DE69902535D1 (de) | 2002-09-19 |
ATE222250T1 (de) | 2002-08-15 |
GT199900102A (es) | 2000-12-22 |
JP2002518385A (ja) | 2002-06-25 |
US6649627B1 (en) | 2003-11-18 |
FR2780057B1 (fr) | 2002-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR018639A1 (es) | Fenoxipropanolaminas, procedimiento para su preparacion y composicion farmaceutica que las contienen, su utilizacion para la manufactura de un medicamentoy compuestos para su exclusivo uso en dicho procedimiento | |
ES2181866T3 (es) | Compuestos heterociclicos sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
UY27516A1 (es) | Bencimidazoles | |
AR004291A1 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
ES2054860T3 (es) | Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos. | |
AR033594A1 (es) | Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios | |
MX9305769A (es) | Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
UY28342A1 (es) | Nuevos compuestos | |
SV2004001690A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
AR077414A2 (es) | Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion | |
PA8582801A1 (es) | Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa | |
CY1107506T1 (el) | Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης | |
AR029942A1 (es) | Compuestos derivados de 1,3-dihidro-2h-indol-2-ona, su utilizacion, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden, medicamentos constituidos por dichos compuestos y compuestos intermediarios | |
UY28765A1 (es) | Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico | |
AR015712A1 (es) | Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas | |
AR009741A1 (es) | Nuevos derivados de la benzamidina, procedimiento para prepararlos, preparados farmaceuticos que los contienen y su empleo como medicamentos. | |
AR009572A1 (es) | Derivados de 3,4,5,6,7,8-hexahidro pirido (4',3':4,5) tieno (2,3-d) pirimidina sustituidos en posicion 3 y su uso | |
UY28974A1 (es) | Derivados heterocíclicos de piperidina, composiciones que los contienen y procedimiento de preparación | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
BR0100234A (pt) | Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
ATE375985T1 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
MX9304424A (es) | Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
AR014146A1 (es) | Compuestos de triazina, su uso en terapia, composiciones farmaceuticas que los contienen, proceso para su manufactura e intermediarios de sintesis | |
AR029637A1 (es) | Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento |